 |
|
|
| |
Retreatment with Telaprevir/Peg-IFN/RBV after a Short Exposure to Telaprevir in Phase I Studies: Interim Results from a Phase IIIb Rollover Trial (C219)
|
| |
| |
Reported by Jules Levin
AASLD SF Nov 5-9 2011
C Sarrazin,1 HW Reesink,2 S Zeuzem,1 CJ Weegink,2 D Luo,3 J Witek,3 TL Kieffer,4 D Bartels,4 I Dierynck,5 S De Meyer,5 G Picchio3
1Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany; 2Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam,
The Netherlands; 3Tibotec Inc., Titusville, NJ, USA; 4Vertex Pharmaceuticals Incorporated, Cambridge, MA, USA; 5Tibotec BVBA, Beerse, Belgium
|
| |
|
|
|
|
|
